Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 6/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.46 |
| ▸ | IDH1 | O75874 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.44 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4115580 | 1.00 | MAPT (0.48) | MAPTLMNASMN1; SMN2GAAMEN1 | |
| SCHEMBL4125117 | 0.95 | MAPT (0.51) | MAPTLMNASMN1; SMN2GAAMEN1 | |
| SCHEMBL4125116 | 0.95 | MAPT (0.51) | MAPTLMNASMN1; SMN2GAAMEN1 | |
| SCHEMBL4108912 | 0.90 | S1PR3 (0.58) | MAPTLMNASMN1; SMN2GAAMEN1 | |
| SCHEMBL4108910 | 0.90 | S1PR3 (0.58) | MAPTLMNASMN1; SMN2GAAMEN1 | |
| SCHEMBL4115547 | 0.89 | MAPT (0.48) | MAPTLMNASMN1; SMN2GAAMEN1 | |
| SCHEMBL4115548 | 0.89 | MAPT (0.48) | MAPTLMNASMN1; SMN2GAAMEN1 | |
| SCHEMBL4118856 | 0.89 | MAPT (0.48) | MAPTLMNASMN1; SMN2GAAMEN1 | |
| SCHEMBL4118859 | 0.89 | MAPT (0.48) | MAPTLMNASMN1; SMN2GAAMEN1 | |
| SCHEMBL4109386 | 0.88 | MAPT (0.43) | MAPTLMNASMN1; SMN2GAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546452-B2 | S1P3 receptor antagonist | TOA EIYO LTD. (JP) | 2013-10-01 | — | — | US | claimed |
| US-20090170895-A1 | S1P3 RECEPTOR ANTAGONIST | TOA EIYO LTD. (JP) | 2009-07-02 | — | — | US | claimed |
| EP-1935874-A1 | S1P3 RECEPTOR ANTAGONIST | TOA EIYO LTD. (JP) | 2008-06-25 | — | — | EP | claimed |
| US-20190117596-A1 | TY-52156 COMPOUNDS FOR THE TREATMENT OF CANCER | WAYNE STATE UNIVERSITY (US) | 2019-04-25 | — | — | US | disclosed |
| WO-2017190077-A1 | TY-52156 COMPOUNDS FOR THE TREATMENT OF CANCER | WAYNE STATE UNIVERSITY (US) | 2017-11-02 | — | — | WO | disclosed |
| US-8546452-B2 | S1P3 receptor antagonist | TOA EIYO LTD. (JP) | 2013-10-01 | — | — | US | disclosed |
| US-20090170895-A1 | S1P3 RECEPTOR ANTAGONIST | TOA EIYO LTD. (JP) | 2009-07-02 | — | — | US | disclosed |
| EP-1935874-A1 | S1P3 RECEPTOR ANTAGONIST | TOA EIYO LTD. (JP) | 2008-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190117596-A1 | TY-52156 COMPOUNDS FOR THE TREATMENT OF CANCER | S1PR3, S1PR1, S1PR4 | MAPT 3528/4885LMNA 3055/4885SMN1; SMN2 2500/4885 |
| US-20090170895-A1 | S1P3 RECEPTOR ANTAGONIST | S1PR3, S1PR5, GPR3 | MAPT 4848/4885LMNA 2613/4885SMN1; SMN2 2497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.